Latest news
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line - TradingViewTradingView · Sat, 08 Aug 2026 00:31:00 GMTRecovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA - MedCity NewsMedCity News · Fri, 07 Aug 2026 22:12:34 GMTReplimune's melanoma drug gets FDA nod but faces legal probe over data practices - PluangPluang · Fri, 07 Aug 2026 16:27:01 GMTFDA Approves Replimune Skin Cancer Drug After Rejections - MedscapeMedscape · Fri, 07 Aug 2026 13:27:22 GMTFDA Approves Twice-Rejected Oncolytic Virus Combination for Melanoma - Oncology News CentralOncology News Central · Fri, 07 Aug 2026 10:27:13 GMTFDA reverses course with accelerated nod for Tudriqev in melanoma - The Pharma LetterThe Pharma Letter · Fri, 07 Aug 2026 10:18:54 GMTThird time lucky for Replimune as FDA OKs melanoma drug - pharmaphorumpharmaphorum · Fri, 07 Aug 2026 09:50:13 GMTUCLA Wins $3.9 Million to Test Drugs That Might Make Melanoma Immunotherapy Work for More Patients - Medical DailyMedical Daily · Fri, 07 Aug 2026 03:30:16 GMT